Ivana Massud1, Amy Martin1, Chuong Dinh1, James Mitchell1, Leecresia Jenkins1, Walid Heneine1, Chou-Pong Pau1, J Gerardo García-Lerma2. 1. Laboratory Branch, Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30329, USA. 2. Laboratory Branch, Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30329, USA ggarcia-lerma@cdc.gov.
Abstract
OBJECTIVES: Pharmacokinetic studies in animal models are important for assessing the prophylactic potential of antiretroviral drugs for HIV prevention. This study sought to identify clinically relevant doses of the marketed integrase inhibitors raltegravir, elvitegravir and dolutegravir in macaques and investigate drug penetration and antiviral activity in mucosal secretions. METHODS: Macaques received one oral dose of raltegravir, elvitegravir or dolutegravir alone or in combination with emtricitabine and tenofovir disoproxil fumarate followed by drug level measurements in blood and rectal and vaginal secretions. Antiviral activity was investigated in TZM-bl cells exposed to SHIV162p3 in the presence of rectal secretions collected from treated animals. RESULTS: Plasma drug concentrations with 50 mg/kg raltegravir or elvitegravir were within the range seen in humans receiving 400-800 mg of raltegravir or 800 mg of unboosted elvitegravir but lower than with 150 mg of elvitegravir boosted with cobicistat. AUC0-24 values for dolutegravir increased proportionally with the dose, with a calculated human-equivalent dose of 20 mg/kg. Elvitegravir showed the highest penetration in rectal and vaginal fluids despite the absence of pharmacological boosting, followed by raltegravir and dolutegravir. Rectal secretions collected at 24 h from treated macaques blocked infection of TZM-bl cells by 50% at dilutions of 1/1000 (raltegravir), 1/800 (dolutegravir) and >1/30 000 (elvitegravir). CONCLUSIONS: We defined macaque doses of HIV integrase inhibitors that recapitulate human clinical doses, which will facilitate efficacy and dose escalation studies in macaques. High and sustained drug concentrations and activity in mucosal secretions suggest that integrase inhibitors are promising candidates for HIV prevention. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy 2015. This work is written by (a) US Government employee(s) and is in the public domain in the US.
OBJECTIVES: Pharmacokinetic studies in animal models are important for assessing the prophylactic potential of antiretroviral drugs for HIV prevention. This study sought to identify clinically relevant doses of the marketed integrase inhibitors raltegravir, elvitegravir and dolutegravir in macaques and investigate drug penetration and antiviral activity in mucosal secretions. METHODS: Macaques received one oral dose of raltegravir, elvitegravir or dolutegravir alone or in combination with emtricitabine and tenofovir disoproxil fumarate followed by drug level measurements in blood and rectal and vaginal secretions. Antiviral activity was investigated in TZM-bl cells exposed to SHIV162p3 in the presence of rectal secretions collected from treated animals. RESULTS: Plasma drug concentrations with 50 mg/kg raltegravir or elvitegravir were within the range seen in humans receiving 400-800 mg of raltegravir or 800 mg of unboosted elvitegravir but lower than with 150 mg of elvitegravir boosted with cobicistat. AUC0-24 values for dolutegravir increased proportionally with the dose, with a calculated human-equivalent dose of 20 mg/kg. Elvitegravir showed the highest penetration in rectal and vaginal fluids despite the absence of pharmacological boosting, followed by raltegravir and dolutegravir. Rectal secretions collected at 24 h from treated macaques blocked infection of TZM-bl cells by 50% at dilutions of 1/1000 (raltegravir), 1/800 (dolutegravir) and >1/30 000 (elvitegravir). CONCLUSIONS: We defined macaque doses of HIV integrase inhibitors that recapitulate human clinical doses, which will facilitate efficacy and dose escalation studies in macaques. High and sustained drug concentrations and activity in mucosal secretions suggest that integrase inhibitors are promising candidates for HIV prevention. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy 2015. This work is written by (a) US Government employee(s) and is in the public domain in the US.
Authors: C C Tsai; P Emau; K E Follis; T W Beck; R E Benveniste; N Bischofberger; J D Lifson; W R Morton Journal: J Virol Date: 1998-05 Impact factor: 5.103
Authors: Edwin DeJesus; Daniel Berger; Martin Markowitz; Calvin Cohen; Trevor Hawkins; Peter Ruane; Richard Elion; Charles Farthing; Lijie Zhong; Andrew K Cheng; Damian McColl; Brian P Kearney Journal: J Acquir Immune Defic Syndr Date: 2006-09 Impact factor: 3.731
Authors: P A Kozlowski; R M Lynch; R R Patterson; S Cu-Uvin; T P Flanigan; M R Neutra Journal: J Acquir Immune Defic Syndr Date: 2000-08-01 Impact factor: 3.731
Authors: C C Tsai; K E Follis; A Sabo; T W Beck; R F Grant; N Bischofberger; R E Benveniste; R Black Journal: Science Date: 1995-11-17 Impact factor: 47.728
Authors: Kelem Kassahun; Ian McIntosh; Donghui Cui; David Hreniuk; Shelia Merschman; Kenneth Lasseter; Neal Azrolan; Marian Iwamoto; John A Wagner; Larissa A Wenning Journal: Drug Metab Dispos Date: 2007-06-25 Impact factor: 3.922
Authors: J Gerardo García-Lerma; Ron A Otten; Shoukat H Qari; Eddie Jackson; Mian-Er Cong; Silvina Masciotra; Wei Luo; Caryn Kim; Debra R Adams; Michael Monsour; Jonathan Lipscomb; Jeffrey A Johnson; David Delinsky; Raymond F Schinazi; Robert Janssen; Thomas M Folks; Walid Heneine Journal: PLoS Med Date: 2008-02 Impact factor: 11.069
Authors: Corbin G Thompson; John K Fallon; Michelle Mathews; Paige Charlins; Leila Remling-Mulder; Martina Kovarova; Lourdes Adamson; Nithya Srinivas; Amanda Schauer; Craig Sykes; Paul Luciw; J Victor Garcia; Ramesh Akkina; Philip C Smith; Angela D M Kashuba Journal: AIDS Date: 2017-07-31 Impact factor: 4.177
Authors: Aaron S Devanathan; Jason R Pirone; Ramesh Akkina; Leila Remling-Mulder; Paul Luciw; Lourdes Adamson; J Victor Garcia; Martina Kovarova; Nicole R White; Amanda P Schauer; Kimberly Blake; Craig Sykes; Erin M Burgunder; Nithya Srinivas; Elias P Rosen; Angela D M Kashuba Journal: Antimicrob Agents Chemother Date: 2019-12-20 Impact factor: 5.191
Authors: Martina Kovarova; Michael D Swanson; Rosa I Sanchez; Caroline E Baker; Justin Steve; Rae Ann Spagnuolo; Bonnie J Howell; Daria J Hazuda; J Victor Garcia Journal: J Antimicrob Chemother Date: 2016-03-21 Impact factor: 5.790